|
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
|
12/29/17
|
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
|
PDF
|
|
Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
|
12/22/17
|
Bausch + Lomb Receives FDA Approval of LUMIFY™ - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
|
PDF
|
|
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
|
12/20/17
|
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
|
PDF
|
|
Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
|
12/18/17
|
Bausch + Lomb Begins Distribution Of VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers
|
PDF
|
|
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
|
12/15/17
|
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
|
PDF
|
|
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
|
12/07/17
|
Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
|
PDF
|
|
Valeant Announces Pricing Of Private Offering Of Senior Notes
|
12/04/17
|
Valeant Announces Pricing Of Private Offering Of Senior Notes
|
PDF
|
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
12/04/17
|
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
|
PDF
|
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
|
12/04/17
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
|
PDF
|
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
12/04/17
|
Valeant Announces Launch Of Private Offering Of Senior Notes
|
PDF
|
|
Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment
|
11/21/17
|
Valeant Announces Closing Of Add-On Secured Notes And Credit Agreement Amendment
|
PDF
|
|
Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference
|
11/21/17
|
Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference
|
PDF
|
|
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
|
11/15/17
|
Bausch + Lomb Helps To Recycle More Than One Million Units Of Contact Lens Materials Within First Year Of Launching The ONE By ONE Recycling Program
|
PDF
|
|
Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
|
11/14/17
|
Valeant Announces Pricing Of Private Offering Of Add-On Secured Notes
|
PDF
|
|
Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
|
11/14/17
|
Ortho Dermatologics Announces Aspire Higher Scholarship Honorees
|
PDF
|
|
Valeant Announces Launch of Private Offering of Add-On Secured Notes
|
11/13/17
|
Valeant Announces Launch of Private Offering of Add-On Secured Notes
|
PDF
|
|
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
|
11/10/17
|
Valeant Pharmaceuticals Completes Sale of Obagi Medical Products Business to Haitong International Zhongua Finance Acquisition Fund I, L.P.
|
PDF
|
|
Valeant To Participate At The Stifel 2017 Healthcare Conference
|
11/08/17
|
Valeant To Participate At The Stifel 2017 Healthcare Conference
|
PDF
|
|
Valeant Announces Third-Quarter 2017 Results
|
11/07/17
|
Valeant Announces Third-Quarter 2017 Results
|
pdf
|
|
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
|
11/06/17
|
Valeant Agrees To Sell Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
|
PDF
|
|
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%
|
11/02/17
|
Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (latanoprostene Bunod Ophthalmic Solution), 0.024%
|
PDF
|
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
|
11/02/17
|
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
|
PDF
|
|
Valeant Will Reduce Debt By Additional $125 Million
|
10/31/17
|
Valeant Will Reduce Debt By Additional $125 Million
|
PDF
|
|
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
|
10/16/17
|
Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes
|
PDF
|
|
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
|
10/12/17
|
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ™ (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
|
PDF
|
|
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology
|
10/04/17
|
Solta Medical Receives FDA 510(k) Clearance for Thermage FLX™ System, Newest Generation Skin Smoothing Technology
|
PDF
|
|
Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe
|
10/03/17
|
Bausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe
|
PDF
|
|
Valeant Will Release Third-Quarter 2017 Financial Results On November 7
|
10/03/17
|
Valeant Will Release Third-Quarter 2017 Financial Results On November 7
|
PDF
|
|
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes
|
10/02/17
|
Valeant Announces Pricing Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
|
10/02/17
|
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,000,000,000 Outstanding Principal Amount
|
PDF
|
|
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
|
10/02/17
|
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group
|
09/29/17
|
Valeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific Equity Partners And The Carlyle Group
|
PDF
|
|
Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans
|
09/27/17
|
Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans
|
PDF
|
|
Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference
|
09/27/17
|
Valeant to Participate at the Deutsche Bank 25th Annual Leveraged Finance Conference
|
PDF
|
|
Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
|
09/18/17
|
Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
|
PDF
|
|
Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
|
09/18/17
|
Valeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
|
PDF
|
|
Valeant Commits $200,000 to Support Hurricane Relief Efforts
|
09/15/17
|
Valeant Commits $200,000 to Support Hurricane Relief Efforts
|
PDF
|
|
Valeant To Participate At The Morgan Stanley Global Healthcare Conference
|
09/06/17
|
Valeant To Participate At The Morgan Stanley Global Healthcare Conference
|
PDF
|
|
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
|
09/05/17
|
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
|
PDF
|
|
Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
|
08/16/17
|
Valeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
|
PDF
|
|
Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy
|
08/09/17
|
Paulson & Co., Inc. Reiterates Confidence In Valeant Strategy
|
PDF
|
|
Valeant Announces Second-Quarter 2017 Results
|
08/08/17
|
Valeant Announces Second-Quarter 2017 Results
|
pdf
|
|
Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA
|
08/07/17
|
Valeant Pharmaceuticals Receives Complete Response Letter from the FDA for Latanoprostene Bunod Ophthalmic Solution, 0.024% NDA
|
PDF
|
|
Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection
|
07/27/17
|
Valeant Announces U.S. Launch of SILIQ™ (brodalumab) Injection
|
PDF
|
|
Valeant Agrees To Sell Obagi Medical Products Business
|
07/17/17
|
Valeant Agrees To Sell Obagi Medical Products Business
|
PDF
|
|
Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018
|
07/13/17
|
Valeant Announces Redemption Of Remaining Approximately $500 Million Aggregate Principal Amount Of Its Outstanding 6.75% Senior Notes Due 2018
|
PDF
|
|
Valeant Announces Q2 2017 Financial Results Date And Conference Call Details
|
07/10/17
|
Valeant Announces Q2 2017 Financial Results Date And Conference Call Details
|
PDF
|
|
Valeant Pays Down $811 Million of Senior Secured Term Loans
|
07/10/17
|
Valeant Pays Down $811 Million of Senior Secured Term Loans
|
PDF
|
|
Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses
|
07/06/17
|
Bausch + Lomb Japan Launches Bausch + Lomb AQUALOX® Contact Lenses
|
PDF
|
|
Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group
|
06/29/17
|
Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group
|
PDF
|
|
Salix Announces Filing Acceptance For Plenvu®* Next Generation Bowel Cleansing Preparation For Colonoscopies
|
06/28/17
|
Salix Announces Filing Acceptance For Plenvu®* Next Generation Bowel Cleansing Preparation For Colonoscopies
|
pdf
|
|
Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
|
06/22/17
|
Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For Second Consecutive Year By Brandspark International
|
PDF
|
|
Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
|
06/19/17
|
Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
|
PDF
|
|
John Paulson Joins Valeant Board Of Directors
|
06/19/17
|
John Paulson Joins Valeant Board Of Directors
|
PDF
|
|
Valeant Announces Sale of iNova Pharmaceuticals for $930 Million
|
06/08/17
|
Valeant Announces Sale of iNova Pharmaceuticals for $930 Million
|
PDF
|
|
Valeant Pharmaceuticals To Present At Financial Industry Conferences
|
05/31/17
|
Valeant Pharmaceuticals To Present At Financial Industry Conferences
|
PDF
|
|
Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution
|
05/22/17
|
Bausch + Lomb Introduces renu® Advanced Formula Multi-Purpose Solution
|
PDF
|
|
Statement Regarding Xifaxan Intellectual Property Litigation
|
05/17/17
|
Statement Regarding Xifaxan Intellectual Property Litigation
|
PDF
|
|
Valeant Pharmaceuticals To Present At Health Care Conferences
|
05/10/17
|
Valeant Pharmaceuticals To Present At Health Care Conferences
|
PDF
|
|
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
|
05/09/17
|
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
|
pdf
|
|
Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%
|
05/08/17
|
Bausch + Lomb Announces PDUFA Date For New OTC Redness Reliever, Brimonidine Tartrate Ophthalmic Solution, 0.025%
|
PDF
|
|
Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
|
05/05/17
|
Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
|
PDF
|
|
Valeant Announces 2017 Annual Meeting Results
|
05/03/17
|
Valeant Announces 2017 Annual Meeting Results
|
pdf
|
|
Valeant Announces Additional Debt Reduction Of Approximately $220 Million
|
05/01/17
|
Valeant Announces Additional Debt Reduction Of Approximately $220 Million
|
PDF
|
|
Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System
|
04/26/17
|
Bausch + Lomb Receives 510(k) Clearance From FDA For Vitesse™, The First And Only Hypersonic, Open-Port Vitrectomy System
|
PDF
|
|
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
|
04/21/17
|
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
|
PDF
|
|
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
|
04/10/17
|
Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
|
PDF
|
|
Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform
|
04/06/17
|
Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite™ Next-Generation Phacoemulsification Platform
|
PDF
|
|
Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced
|
03/30/17
|
Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced
|
PDF
|
|
Valeant Completes Refinancing Transactions
|
03/21/17
|
Valeant Completes Refinancing Transactions
|
PDF
|
|
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018
|
03/20/17
|
Valeant Announces the Early Results of Tender Offers for Its 6.75% Senior Notes Due 2018
|
PDF
|
|
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod
|
03/20/17
|
Bausch + Lomb And Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod
|
PDF
|
|
Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses
|
03/15/17
|
Bausch + Lomb Introduces Biotrue® ONEday For Astigmatism Contact Lenses
|
PDF
|
|
Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement
|
03/10/17
|
Valeant Receives Lender Consent For Refinancing And Amendment Of Credit Agreement
|
PDF
|
|
Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018
|
03/10/17
|
Valeant Announces Upsizing Of Cash Tender Offer For Its 6.75% Senior Notes Due 2018
|
PDF
|
|
Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes
|
03/10/17
|
Valeant Announces Pricing And Upsize Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
|
03/09/17
|
Valeant Announces Launch Of Private Offering Of Senior Secured Notes
|
PDF
|
|
Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018
|
03/07/17
|
Valeant Commences Cash Tender Offer For Up To $600,000,000 Outstanding Principal Amount Of Its 6.75% Senior Notes Due 2018
|
PDF
|
|
Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement
|
03/06/17
|
Valeant Completes Approximately $1.1 Billion Pay Down Of Senior Secured Term Loans From Divestitures; To Seek Refinancing And Amendment Of Credit Agreement
|
PDF
|
|
Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal
|
03/03/17
|
Valeant Pharmaceuticals Completes Sale Of CeraVe, AcneFree And AMBI Skincare Brands To L'Oréal
|
PDF
|
|
Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation
|
03/01/17
|
Valeant Pharmaceuticals Corrects Misleading Report About Salix Investigation
|
PDF
|
|
Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
|
02/28/17
|
Valeant Reports Fourth Quarter And Full Year 2016 Financial Results And Provides 2017 Guidance
|
pdf
|
|
Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity
|
02/27/17
|
Valeant Announces Deployment Of Expanded Salix Sales Force To Capture Untapped Market Opportunity
|
PDF
|
|
Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
|
02/27/17
|
Bausch + Lomb And Nicox Resubmit US New Drug Application For Novel Glaucoma Candidate Latanoprostene Bunod
|
PDF
|
|
Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products
|
02/23/17
|
Obagi Medical Products Announces Collaboration With Suzan Obagi, M.D., And Nextcell Medical To Introduce New Line Of Products
|
PDF
|
|
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
|
02/21/17
|
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
|
PDF
|
|
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
|
02/16/17
|
Valeant Receives FDA Approval Of SILIQ™ (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
|
PDF
|
|
Valeant Pharmaceuticals To Participate At Healthcare Conferences
|
02/13/17
|
Valeant Pharmaceuticals To Participate At Healthcare Conferences
|
PDF
|
|
Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance
|
01/30/17
|
Valeant To Hold Conference Call To Present Fourth Quarter And Full Year 2016 Results And Announce 2017 Guidance
|
PDF
|
|
Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses
|
01/10/17
|
Bausch + Lomb Launches Expanded Parameters For Bausch + Lomb ULTRA® For Presbyopia Contact Lenses
|
PDF
|
|
Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118
|
01/10/17
|
Valeant Pharmaceuticals Announces Results Of Second Phase 3 Study For Psoriasis Treatment IDP-118
|
PDF
|
|
Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion
|
01/10/17
|
Valeant To Sell CeraVe, AcneFree And AMBI Skincare Brands To L'Oreal For $1.3 Billion
|
PDF
|
|
Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash
|
01/09/17
|
Valeant To Sell Dendreon To Sanpower Group For $819.9 Million In Cash
|
PDF
|
|
Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
|
01/04/17
|
Valeant Pharmaceuticals To Present At The 35th Annual J.P. Morgan Healthcare Conference
|
PDF
|
|
Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors
|
01/04/17
|
Valeant Pharmaceuticals Announces Addition Of Richard U. DeSchutter To Its Board Of Directors
|
PDF
|
